Clinical Trial Update: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections [Phase 3]

View source ↗

Summary

Phase 3 trial comparing brolucizumab 6 mg every 4 weeks to aflibercept 2 mg every 4 weeks in patients with retinal fluid despite frequent anti-VEGF injections i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Brolucizumab (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-Related Macular Degeneration | Phase 3 | Status: TERMINATED | Results posted: 2022-07-22